This Market Spotlight report covers the Zika virus market, comprising key pipeline therapies, clinical trials, probability of success, epidemiology, and licensing and acquisition deals.
- The Zika virus was first reported in continental South America in Brazil in May 2015. In February 2016, between 440,000 and 1,300,000 people were infected in Brazil. In the US, about 225 Zika virus cases were reported in August 2017. In addition, 554 cases were reported in people infected through local mosquito-borne transmission. Furthermore, autochthonous Zika virus transmission was reported in 25 countries in the Americas, Africa, and Asia.
- In 2016, it was estimated that there were between 508 and 1,778 imported cases in Europe, particularly in France, Portugal, and Italy.
- The majority of industry-sponsored drugs in active clinical development for Zika virus are in Phase I, with just a single product in Phase II.
- Therapies in early-to-mid-stage development for Zika virus focus on the immune system and viral antigens. Candidates comprise DNA vaccines such as the National Institutes of Health’s Zika Virus Vaccine, GeneOne’s GLS-5700, and Inovio’s INO-A002; Moderna’s mRNA vaccine; Themis Bioscience’s recombinant viral vector vaccine; Imutex’s AGS-v vaccine; Johnson & Johnson’s Ad26.ZIKV.001 vaccine; Takeda’s TAK-426 vaccine; Emergent BioSolutions’ ZIKV-IG; Valneva’s ZIKV-VLA1601; and BioCryst’s galidesivir, a broad-spectrum antiviral drug.
- The overall likelihood of approval of a Phase I antiviral asset is 16.6%, and the average probability a drug advances from Phase III is 77.6%. Drugs, on average, take 8.8 years from Phase I to approval, compared to 9.0 years in the overall infectious disease space.
- There have been 11 licensing and asset acquisition deals involving Zika virus drugs during 2014–19, all of which occurred in either 2016 or 2017. The exclusive 2017 agreement between Emergent BioSolutions and Valneva, worth $58.3m, for the global rights to Valneva’s Zika vaccine technology and ZIKV-VLA1601, was the largest deal during the period.
- All clinical trials for Zika virus have been in either Phase I or Phase II, with no Phase III trials to date.
- The US leads in terms of the number of Zika virus clinical trials globally. The largest share of industry-sponsored clinical trials are ongoing. Takeda and GeoVax have planned one trial each in the Zika virus space.
- Inovio and Sanofi lead industry sponsors with three clinical trials each for Zika virus
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
11 PIPELINE DRUGS
17 PROBABILITY OF SUCCESS
18 LICENSING AND ASSET ACQUISITION DEALS
18 GeoVax Collaborates With Enesi Pharma On Needle-Free Vaccines
19 Bridging The Gap: Cyclenium Pharma
19 Brazil’s Oneway Diagnostica, iBio Collaborate On Virus Diagnostics
20 CLINICAL TRIAL LANDSCAPE
21 Sponsors by status
22 Sponsors by phase
23 Recent events
10 Figure 1: Recent epidemiological updates
10 Figure 2: Zika cases timeline
LIST OF FIGURES
11 Figure 3: Overview of pipeline drugs for Zika virus in the US
12 Figure 4: Pipeline drugs for Zika virus, by company
12 Figure 5: Pipeline drugs for Zika virus, by drug type
12 Figure 6: Pipeline drugs for Zika virus, by classification
17 Figure 7: Probability of success in the Zika virus pipeline
18 Figure 8: Licensing and asset acquisition deals in Zika virus, 2014–19
20 Figure 9: Clinical trials in Zika virus
20 Figure 10: Top 10 drugs for clinical trials in Zika virus
21 Figure 11: Top 10 companies for clinical trials in Zika virus
21 Figure 12: Zika virus trial locations
22 Figure 13: Zika virus trials status
23 Figure 14: Zika virus trials sponsors, by phase
LIST OF TABLES
14 Table 1: Pipeline drugs for Zika virus in the US